CN100340309C - Biological induction type active artificial cornea, and application method therefor - Google Patents
Biological induction type active artificial cornea, and application method therefor Download PDFInfo
- Publication number
- CN100340309C CN100340309C CNB021153167A CN02115316A CN100340309C CN 100340309 C CN100340309 C CN 100340309C CN B021153167 A CNB021153167 A CN B021153167A CN 02115316 A CN02115316 A CN 02115316A CN 100340309 C CN100340309 C CN 100340309C
- Authority
- CN
- China
- Prior art keywords
- cornea
- artificial cornea
- active artificial
- induction type
- type active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004087 cornea Anatomy 0.000 title claims abstract description 88
- 230000006698 induction Effects 0.000 title claims description 42
- 238000000034 method Methods 0.000 title abstract description 20
- 102000008186 Collagen Human genes 0.000 claims abstract description 25
- 108010035532 Collagen Proteins 0.000 claims abstract description 25
- 229920001436 collagen Polymers 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920001661 Chitosan Polymers 0.000 claims abstract description 15
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 13
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 13
- 239000003102 growth factor Substances 0.000 claims abstract description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 16
- 102000013275 Somatomedins Human genes 0.000 claims description 16
- 238000009395 breeding Methods 0.000 claims description 8
- 230000001488 breeding effect Effects 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 5
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 5
- 238000002513 implantation Methods 0.000 claims description 5
- 150000001718 carbodiimides Chemical class 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 230000010307 cell transformation Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 abstract description 16
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 238000000465 moulding Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 8
- 229930182566 Gentamicin Natural products 0.000 description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 241000425571 Trepanes Species 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种生物诱导型活性人工角膜，包括如下组分：壳聚糖0.5%～3%、胶原0.5%～3%、透明质酸0.1%～0.5%、水93.5%～98.8%，以上比例为重量百分比；为助于刺激自体生长因子富集速度，也可先在材料上整合角膜生长因子；一种生物诱导型活性人工角膜的使用方法，具体步骤为直接将生物诱导型活性人工角膜移植入人眼。本生物诱导型活性人工角膜具有与人眼角膜相似的特性，与眼组织的相容性好，适合成型加工，制作过程简单，并易于长期保存和长途输运，社会与经济效益较好；本人工角膜的使用方法简单方便、安全可靠，作用效果较好，还为其它生物诱导型活性人工组织的研究开辟了道路，具有重要的科学意义。The invention provides a biologically induced active artificial cornea, comprising the following components: 0.5%-3% chitosan, 0.5%-3% collagen, 0.1%-0.5% hyaluronic acid, 93.5%-98.8% water, more than The ratio is percentage by weight; in order to help stimulate the enrichment speed of the autologous growth factor, corneal growth factor can also be integrated on the material; a method for using a biologically induced active artificial cornea, the specific steps are directly adding the biologically induced active artificial cornea Transplanted into the human eye. The biologically induced active artificial cornea has the characteristics similar to the human cornea, has good compatibility with eye tissue, is suitable for molding and processing, has a simple production process, and is easy to store and transport for a long time, and has good social and economic benefits; The use method of the artificial cornea is simple, convenient, safe and reliable, and the effect is good. It also opens up a way for the research of other biologically induced active artificial tissues, and has important scientific significance.
Description
(1) technical field
The present invention relates to artificial cornea's technology, particularly a kind of biological induction type active artificial cornea and using method thereof.
(2) background technology
Keratopathy is the present principal element of eye blinding, and global patient has 1,000 ten thousand people approximately, China 3,000,000 corneal blindness patients that also have an appointment.But because the scarcity of donor source, the allogeneic keratoplasty that China can carry out every year only is about 1000 examples, and a large amount of patients can not get curing because of the shortage of human cornea, and this is a global long-term unsolved problem.Because the no blood vessel characteristic of eye immune privilege phenomenon and cornea, keratoplasty is the highest operation of success rate in body tissue's organ transplantation, and therefore, artificial cornea and transplanting thereof are better than the transplanting of other organizational project organs and tissue.Present existing artificial cornea has two kinds of nonactive artificial cornea and the epigamic tissue engineering artificial corneals of inanimate object, the artificial cornea that nonactive artificial cornea utilizes synthetic material such as methyl methacrylate (MMA) etc. to make, when carrying out the human implantation, though can make people's vision recovers to some extent, but field range is minimum, synthetic material is difficult to merge with enclosing near the eyes to organize mutually, foreign body sensation is arranged after the implantation, corneal solution, leakage of aqueous humor appear easily, the artificial cornea deviates from and complication such as endophthalmitis, brings very big misery to the patient.And common notional tissue engineering artificial corneal is under the condition of external reinforcement, carries out keratocyte and cultivates, and the cell of In vitro culture just makes it biologically active after growth on the timbering material; Though the artificial cornea that this method is produced may make moderate progress aspect the histocompatibility with enclosing near the eyes, but because it needs the multiple keratocyte of In vitro culture, and the approaches and methods of acquisition of keratocyte at present and cultivation is relatively more difficult and immature, the preservation after keratocyte is cultivated and the also existing problems of breeding that go down to posterity, whole process is complicated, expense is high, and the immunologic rejection effect of allosome keratocyte in migration process also is a great problem that faces.
(3) summary of the invention
The objective of the invention is to overcome the shortcoming of prior art, but provide a kind of and people ocular tissue have excellent biological compatibility, need not be at external cell culture, easy to use, functional and long preservation and long-distance transporting, the biological induction type active artificial cornea of being convenient to carry out large-scale production and realizing industrialization of carrying out.
Another object of the present invention is to provide the using method and the technology of above-mentioned biological induction type active artificial cornea.
Purpose of the present invention is achieved through the following technical solutions: this biological induction type active artificial cornea comprises following component---
Chitosan 0.5%～3%
Collagen 0.5%～3%
Hyaluronic acid 0.1%～0.5%
Water 93.5%～98.8%
Above ratio is weight percentage.
Except that above-mentioned component, for helping stimulate speed from the enrichment of the bulk-growth factor, this biological induction type active artificial cornea also can be integrated with the keratocyte somatomedin as becoming very thin somatomedin (FGF), epithelical cell growth factor (EGF) and cell transformation somatomedin (TGF-β
1), consumption is 3～100ng/ml, the carbodiimide with 0.01%～0.2% (EDC) cross-linking agent is crosslinked, forms the biological induction type active artificial cornea of band somatomedin.
The method for preparing above-mentioned biological induction type active artificial cornea comprises the steps: that (1) is dissolved in acid solution with chitosan, and collagen and hyaluronic acid are water-soluble; (2) mix each component; (3) mixed liquor is injected mould and oven dry; (4) be soaked in water behind cleaning, drying resulting product and make it reach the suction balance.
Behind each component mix homogeneously of step 2, can add the keratocyte somatomedin.
The using method of above-mentioned biological induction type active artificial cornea is: directly this biological induction type active artificial cornea is implanted into human eye, before transplanting, need carry out the cultivation of external keratocyte; After being implanted into human eye, this biological induction type active artificial cornea is organized mutually with cornea and is merged, induce the enrichment of multiple keratocyte somatomedin, stimulate keratocyte growth and breeding thereon, the degraded synchronized development of the growth of keratocyte and artificial cornea's material, final whole artificial cornea's length of a film becomes cornea tissue.
Particularly, the using method of above-mentioned biological induction type active artificial cornea is soaked biological induction type active artificial cornea 12～48 hours at sterile distilled water before comprising the steps: to transplant in advance, make it reach the suction balance, reuse medicining liquid dipping 2～3 days, carry out the preceding aseptic sterilization of art, transplant according to clinical requirement then.
Described disinfectant solution is the mixed liquor of normal saline and gentamycin sulfate.
Action principle of the present invention is: people's cornea tissue mainly is made of epithelial cell, fibroblast, endotheliocyte and collagen fiber and mucopolysaccharide, collagen protein accounts for 75% of cornea dry weight, can from animal, extract in a large number, the source is abundant and the charge is small, therefore adopts the host material of collagen as this artificial CF.
The collagen that from animal, extracts, though similar to human collagen on forming, variation has taken place in its overall structure in leaching process, the collagen after the purification has lost intensity, as the backing substrate material, is subjected to the effect of collagenase in vivo, very easily degraded; In order to remedy these weakness of collagen, strengthen intensity and its degradation rate in vivo of control of collagen, take to add the method for chitosan; Chitosan is a kind of natural biological aminopolysaccharide, to the mucopolysaccharide in the matter between keratocyte similar structure is arranged, good film-forming property, intensity height, appearance transparent, in body not by degraded by collagenase, can be degraded by lysozyme lentamente, thereby can regulate the degradation rate of backing substrate material, it is crosslinked also can to use cross-linking agent that material is carried out simultaneously, the control degradation rate.
Hyaluronic acid belongs to mucopolysaccharide; it is to constitute outside the keratocyte and the main component of intercellular matrix; have viscoelasticity and macromole hydrability; can promote growth and breeding with the pilot angle theca cell; network structure corneal form and the keeping of normal physiological state that forms that combine with collagen has important function; by with the combining of corneal endothelium; form the protecting film on cornea tissue surface; the damage that the radical pair keratocyte causes in the control volume; the hydroxyl that contains in the mucopolysaccharide composition on a large amount of electronegative carboxyls and eye surface in the hyaluronan molecule is easy to and the surperficial affinity of eye by hydrogen bonded.
The cultivation of somatomedin corneal cell, growth and breeding reach the great influence that is combined with extracellular and intercellular matrix, the cooperative effect between the different keratocyte somatomedin and the growth and breeding of consumption corneal cell can be regulated and control, wherein fibroblast growth factor (FGF), transforming growth factor (TGF-β
1), and the growth and breeding of epidermal growth factor (EGF) corneal cell, intercellular normal fusion and facilitation is all arranged with combining of substrate.
The present invention has following advantage with respect to prior art: (1) biological induction type active artificial cornea of the present invention and ocular tissue have the good compatibility, merge mutually with the cornea cell, induce the enrichment of multiple keratocyte somatomedin, stimulate keratocyte growth and breeding thereon; Before corneal transplantation and repairing, need not carry out the cultivation of external keratocyte, thereby exempted the complex process of In vitro culture keratocyte and transplanted the immunological rejection cause by the allosome keratocyte, and the various complication that produce therefrom, so use not only simple and convenient, and as safe as a house reliable, action effect is better; (2) this biological induction type active artificial cornea has optics similar to eye cornea and mechanical characteristic, can carry out various machine-shapings according to relevant requirements, can be used as the comparatively ideal succedaneum of eye cornea; The optics mechanical index of the biological induction type active artificial cornea of having made is similar to people's cornea, as follows: material light transmittance: 90～96%; Material refractive index: 1.368～1.382 (eye cornea is 1.377); Mechanical strength and eye cornea are similar, wherein hygrometric state tensile strength: 4Mpa～8.6MPa; Moisture content: 55～75%; Elongation at break: 300%～350%; (3) this biological induction type active artificial cornea relatively is fit to processing and forming, and manufacturing process is simple, handling ease is convenient, so can prepare use in large quantity; (4) this biological induction type active artificial cornea is easy to long preservation and long-distance transporting, and is convenient to carry out large-scale production and realizes industrialization; (5) invention of this biological induction type active artificial cornea, not only important facilitation is arranged for people ' s health, can produce important society and economy benefit, but also opened up road for the research of other biological induction type active artificial organ, as adopt similar biotic induce method can realize the direct implantation of other artificial organ, thereby has important scientific meaning.
(4) specific embodiment
Below in conjunction with embodiment the present invention is done further concrete description, but embodiments of the present invention are not limited thereto.
Embodiment 1
The ratio of each component of this biological induction type active artificial cornea is as follows:
Chitosan 2%
Collagen 2.5%
Hyaluronic acid 0.3%
Water 95.1%
Above ratio is weight percentage.
The process for preparing this biological induction type active artificial cornea with above-mentioned each component comprises the steps: that (1) takes by weighing each component by above-mentioned consumption, and chitosan is dissolved in hydrochloric acid solution, and collagen and hyaluronic acid is water-soluble; (2) chitosan salt acid solution and collagen and hyaluronic aqueous solution were at room temperature stirred 1.5 hours, make the abundant mix homogeneously of each component; (3) the carbodiimide cross-linking agent of adding 0.1% in the mixed liquor of mix homogeneously, 90ng/ml becomes very thin somatomedin, and 35ng/ml epithelical cell growth factor and 60ng/ml cell transformation somatomedin fully mix half an hour again; (4) mixed liquor is injected ready-formed cornea mould, fill with and take out after putting it into drying in oven behind the cornea mould; (5) with the cornea goods of clear water soaking and washing oven dry back gained removing residual impurity, and make it in water, place 24～48 hours to reach the suction balance, take out then and promptly make this biological induction type active artificial cornea.
The using method of this biological induction type active artificial cornea is: the biological induction type active artificial cornea material is soaked 24h at sterile distilled water in advance, make it reach the suction balance, cut the sequin that is cut into thickness 0.3～0.5mm with 8mm diameter trepan, with normal saline and gentamycin sulfate mixed liquid dipping 2～3 days, carry out aseptic sterilization before the art.Transplant according to clinical requirement then, enclose near the eyes with iodine tincture sterilization receptor during transplanting, splash into 1～2 cocaine eye drop anaesthetic at its ophthalmic and carry out local anesthesia; Postoperative subconjunctival injection dexamethasone and gentamycin sulfate are coated with tetracycline cortisone ointment in the conjunctival sac; Postoperative drips and be coated with gentamycin sulfate eye drop and tetracycline cortisone ointment every day, or subconjunctival injection dexamethasone and gentamycin sulfate, keeps for 6～8 weeks, the back drug withdrawals of 8 weeks, and be 1～12 month observing time, as finding rejection, i.e. repeated drug taking.
Embodiment 2
The ratio of each component of this biological induction type active artificial cornea is as follows:
Chitosan 1%
Collagen 3%
Hyaluronic acid 0.2%
Water 95.65%
Above ratio is weight percentage.
The process for preparing this biological induction type active artificial cornea with above-mentioned each component comprises the steps: that (1) takes by weighing each component by above-mentioned consumption, and chitosan is dissolved in acetum, and collagen and hyaluronic acid is water-soluble; (2) chitosan-acetic acid solution and collagen and hyaluronic aqueous solution were at room temperature stirred 2 hours, make the abundant mix homogeneously of each component; (3) the carbodiimide cross-linking agent of adding 0.15% in the mixed liquor of mix homogeneously, 5ng/ml becomes very thin somatomedin, and 20ng/ml epithelical cell growth factor and 10ng/ml cell transformation somatomedin fully mix half an hour again; (4) mixed liquor is injected ready-formed cornea mould, fill with and take out after putting it into drying in oven behind the cornea mould; (5) with the cornea goods of clear water soaking and washing oven dry back gained removing residual impurity, and make it in water, place 24～48 hours to reach the suction balance, take out then and promptly make this biological induction type active artificial cornea.
The using method of this biological induction type active artificial cornea is with embodiment 1.
Embodiment 3
The ratio of each component of this biological induction type active artificial cornea is as follows:
Chitosan 0.5%
Collagen 1.5%
Hyaluronic acid 0.3%
Water 97.7%
Above ratio is weight percentage.
The process for preparing this biological induction type active artificial cornea with above-mentioned each component comprises the steps: that (1) takes by weighing each component by above-mentioned consumption, and chitosan is dissolved in acetum, and collagen and hyaluronic acid is water-soluble; (2) chitosan-acetic acid solution and collagen and hyaluronic aqueous solution were at room temperature stirred 2 hours, make the abundant mix homogeneously of each component; (3) mixed liquor is injected ready-formed cornea mould, fill with and take out after putting it into drying in oven behind the cornea mould; (4) with the cornea goods of clear water soaking and washing oven dry back gained removing residual impurity, and make it in water, place 24～48 hours to reach the suction balance, take out then and promptly make this biological induction type active artificial cornea.
The using method of this biological induction type active artificial cornea is with embodiment 1.
Embodiment 4
The ratio of each component of this biological induction type active artificial cornea is as follows:
Chitosan 1.5%
Collagen 2%
Hyaluronic acid 0.1%
Water 96.4%
Above ratio is weight percentage.
The process for preparing this biological induction type active artificial cornea with above-mentioned each component comprises the steps: that (1) takes by weighing each component by above-mentioned consumption, and chitosan is dissolved in acetum, and collagen and hyaluronic acid is water-soluble; (2) chitosan-acetic acid solution and collagen and hyaluronic aqueous solution were at room temperature stirred 2 hours, make the abundant mix homogeneously of each component; (3) mixed liquor is injected ready-formed cornea mould, fill with and take out after putting it into drying in oven behind the cornea mould; (4) with the cornea goods of clear water soaking and washing oven dry back gained removing residual impurity, and make it in water, place 24～48 hours to reach the suction balance, take out then and promptly make this biological induction type active artificial cornea.
The using method of this biological induction type active artificial cornea is with embodiment 1.
The transplanting result who observes the various embodiments described above is as can be known: the biological induction type artificial cornea material of implantation can be compatible with cornea, and is bonding between cornea and the material, with cornea mutually adhesion the visible keratocyte in material place and grow to material internal; Two months degradation rates in vivo of material are about 30%.Taking out dyeing after 90 days makes the result that the pathology section observes and show under optical microscope: cornea structure is normal, the NIP cell, epithelium does not have and thickens and attenuation, essential layer does not have edema, interior skin structure is normal, material has substantially all grown up to cornea tissue, with former cornea tissue good transition is arranged, and does not see difference.
Claims (3)
1, a kind of biological induction type active artificial cornea comprises following component:
Chitosan 0.5%～3%
Collagen 0.5%～3%
Hyaluronic acid 0.1%～0.5%
Water 93.5%～98.8%
Above ratio is weight percentage.
2, according to the described biological induction type active artificial cornea of claim 1, it is characterized in that: being integrated with to stimulate in the inductor keratocyte breeding of growing into, the keratocyte somatomedin that makes it need not carry out the cell in vitro cultivation before implantation.
3, according to the described biological induction type active artificial cornea of claim 2, it is characterized in that: described keratocyte somatomedin is a fibroblast growth factor (FGF), epithelical cell growth factor and cell transformation somatomedin, consumption is respectively 3～100ng/ml, and is crosslinked with 0.01%～0.2% carbodiimide cross-linking agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021153167A CN100340309C (en) | 2002-05-31 | 2002-05-31 | Biological induction type active artificial cornea, and application method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021153167A CN100340309C (en) | 2002-05-31 | 2002-05-31 | Biological induction type active artificial cornea, and application method therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1461658A CN1461658A (en) | 2003-12-17 |
| CN100340309C true CN100340309C (en) | 2007-10-03 |
Family
ID=29742340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021153167A Expired - Lifetime CN100340309C (en) | 2002-05-31 | 2002-05-31 | Biological induction type active artificial cornea, and application method therefor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100340309C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100512889C (en) * | 2006-12-08 | 2009-07-15 | 华南理工大学 | Process of making cornea histoengineering support in bionic structure |
| CN102600495A (en) * | 2011-01-19 | 2012-07-25 | 北京博恩康生物科技有限公司 | Absorbable hemostatic composition and preparation method thereof |
| CN103272268B (en) * | 2013-05-16 | 2015-04-22 | 华南理工大学 | Antibacterial cornea repairing material and preparation method thereof |
| CN115006595B (en) * | 2022-06-28 | 2024-02-06 | 济南金泉生物科技有限公司 | Composite high-performance decellularized cornea and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05220213A (en) * | 1992-02-13 | 1993-08-31 | Nippon Soda Co Ltd | Chitosan derivative-containing artificial blood vessel |
| US5522888A (en) * | 1986-10-16 | 1996-06-04 | Cbs Lens, A California General Partnership | Collagen-hydrogel for promoting epithelial cell growth and regeneration of the stroma |
| JPH09173362A (en) * | 1995-12-25 | 1997-07-08 | Menicon Co Ltd | Artificial skin |
| JPH1076000A (en) * | 1996-09-06 | 1998-03-24 | Agency Of Ind Science & Technol | Cell adhesive and hyperplastic medical treatment article |
-
2002
- 2002-05-31 CN CNB021153167A patent/CN100340309C/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5522888A (en) * | 1986-10-16 | 1996-06-04 | Cbs Lens, A California General Partnership | Collagen-hydrogel for promoting epithelial cell growth and regeneration of the stroma |
| JPH05220213A (en) * | 1992-02-13 | 1993-08-31 | Nippon Soda Co Ltd | Chitosan derivative-containing artificial blood vessel |
| JPH09173362A (en) * | 1995-12-25 | 1997-07-08 | Menicon Co Ltd | Artificial skin |
| JPH1076000A (en) * | 1996-09-06 | 1998-03-24 | Agency Of Ind Science & Technol | Cell adhesive and hyperplastic medical treatment article |
Non-Patent Citations (1)
| Title |
|---|
| 天然大分子及其生物材料在组织工程中的应用 李沁华，现代康复，第5卷第6期 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1461658A (en) | 2003-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10052350B2 (en) | Fabrication of gelatin hydrogel sheet for the transplantation of corneal endothelium | |
| TWI388349B (en) | Ophthalmic devices and related methods and compositions | |
| CN101302486B (en) | Acetobacter xylinum and method for preparing nanocellulose skin tissue repair material using it | |
| CN104958783B (en) | A kind of natural polysaccharide based aquagel and preparation and the application in eye conjunctiva reparation | |
| CN102166375B (en) | Reconstruction method of tissue engineering human corneal epithelium | |
| CN101508971B (en) | Tissue engineering reconstruction method for human corneal endothelium | |
| CN101433478A (en) | Whole layer biological cornea as well as construction method and use thereof | |
| CN101380486B (en) | Active regeneration artificial cornea implant and preparation method thereof | |
| CN102807965B (en) | Method for preparing tissue engineered cornea and device of method | |
| CN106860919A (en) | De- cell amnion of crosslinking and its preparation method and application | |
| CN1218755C (en) | Stem cell regenerating surface cornea and its application in corneal transplantation | |
| CN106421908B (en) | A kind of preparation method of de- cell cornea | |
| CN106591235A (en) | Method for promoting function and characteristic of corneal endothelial cells | |
| CN1473551A (en) | Artificial tissue engineeing biological cornea | |
| CN101543642B (en) | Collagen-based interpenetrating polymer network tissue engineering cornea substitute and preparation method thereof | |
| CN100340309C (en) | Biological induction type active artificial cornea, and application method therefor | |
| CN1382425A (en) | Biologically induced artificial active cornea and its preparing process | |
| CN104941001A (en) | Biological film corneal patch and preparation method and application thereof | |
| CN106282094B (en) | The method that the precursor in application on human skin source is induced to differentiate into corneal endothelium like cell | |
| CN101480505A (en) | Method for preparing surface-functionalized chitosan cornea repair material | |
| CN105148325A (en) | New cornea tissue repair material and preparing method thereof | |
| CN100512889C (en) | Process of making cornea histoengineering support in bionic structure | |
| CN103239762B (en) | Chitin membrane and application of chitin membrane in ophthalmologic treatment | |
| CN108939161B (en) | A kind of humanization activity goes the preparation method of cell corneal stroma stent | |
| CN117100913A (en) | Low-swelling decellularized cornea and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20071003 |
|
| CX01 | Expiry of patent term |